作者: sarah

NEC and ClimateAi Develop Conceptual Model to Promote Climate Change Adaptation in Agriculture

Tokyo, Japan, August 19, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), in collaboration with ClimateAi, a San Francisco-based startup that built the first climate resilience platform, has developed a conceptual model to estimate the effectiveness of climate change adaptation measures for cocoa and rice cultivation in Africa. In this project, ClimateAi’s long-term climate change forecasting technology, which models both the impact of climatic factors on agricultural production and the effectiveness of adaptation measures, was combined with NEC’s expertise in agricultural technology (agritech) to successfully quantify the impact of climate change on agriculture and clarify the return on investment for adaptation measures.This achievement will be showcased at the TICAD Business Expo & Conference (Japan Fair), one of the thematic events of the Ninth Tokyo International Conference on African Development (TICAD 9) to be held in Yokohama, Japan, in August 2025, conveying the significance of utilizing digital technology to address the challenges facing African agriculture (*1).Background and purposeGlobally, while greenhouse gas emission reductions and credit trading are actively being conducted to mitigate the effects of climate change, the implementation of adaptation measures to prevent or reduce damage caused by climate change has not yet progressed. This is due in part to the difficulties involved in assessing the investment cost-effectiveness of implementing adaptation measures.Notably, although the agricultural sector is an industry highly susceptible to climate change, estimating the return on investment for adaptation measures, such as the introduction of irrigation facilities or changes in crop varieties, has thus far proven difficult due to the wide range of factors affecting crop growth, including temperature, water, and soil.NEC and ClimateAi have developed a conceptual model that analyzes various factors affecting agricultural growth using AI and calculates the economic return on investment for adaptation measures. Utilizing this model enables the implementation of adaptation measures that focus on areas where positive effects are expected, promoting local agriculture efficiently and sustainably.OverviewThis newly developed conceptual model was used to analyze adaptation measures targeting the cultivation of cocoa and rice in various locations in Africa. Africa is the world’s largest cocoa producer, with agriculture being one of its major industries. However, due to the impacts of climate change, the cultivation environment for cocoa and rice is expected to change significantly in the coming decades. This initiative focused on the following three adaptation measures to examine their ability to maintain and enhance yields and create economic value in a changing climate.Introduction of irrigation facilitiesChanging to climate-adapted varietiesChanging of planting time for traditionally cultivated varietiesSome of the analysis results can be verified through interactive demonstrations. As an example of potential applications for this conceptual model, it is envisioned that international organizations and development banks providing local agricultural support will utilize it to explore farmland in recipient areas and estimate the effects of implementing adaptation measures.Beyond this example, the system is designed to cater to the needs of various stakeholders involved in agriculture, enabling them to make data-driven decisions.Results and future prospectsThe utilization of AI made it possible to analyze the cost-effectiveness of adaptation measures, such as the introduction of irrigation facilities and changes in cultivation varieties in rice farming across various regions, as well as effective adaptation strategies for cacao cultivation.Significant funding is required to advance climate change adaptation in agriculture. It has been pointed out that in addition to the need for financial support from international organizations, development banks, and governments, the mobilization of private investment is necessary. To provide continuous funding, it is essential to quantify the investment returns from adaptation measures and to conduct proper monitoring and intervention following their implementation.While exploring opportunities for collaborations with businesses that provide irrigation equipment and seedlings, NEC and ClimateAi aim to leverage digital technology use cases to promote financing for climate change adaptation and expand data-driven agritech businesses.Adaptation finance businessSupport for understanding risks to agricultural yields to reduce entry barriers for the private sector / Support for evaluating business feasibility for financingAgritech businessSupport for agricultural producers and managers of climate change adaptation / Support for climate change adaptation in the upstream (seed and agricultural material businesses) and downstream (processing businesses, etc.) of the agricultural supply chainOther businessSupport for climate change adaptation in the infrastructure industry and manufacturing supply chainsThe results of this initiative will be announced at the TICAD Business Expo & Conference (Japan Fair) and other events to gather feedback from the market and proceed with discussions toward commercialization. Going forward, NEC and ClimateAi will work together to scientifically assess the impact of climate change on agriculture and present concrete solutions to achieve sustainable agriculture and food security. Both companies will continue striving to solve global agricultural challenges through technological innovation and data utilization.NEC’s new business development, under the key message "The future is ours to shape," is advancing NEC Open Innovation (*2) through diverse co-creation with a wide range of startups and partner companies. NEC’s collaboration with ClimateAi is one such initiative. By uniting innovative technologies with cross-domain collaboration, NEC continues to create new social value and shape the future.(*1)NEC to participate in "TICAD Business Expo and Conference" and thematic events for TICAD 9 https://www.nec.com/en/press/202508/global_20250805_03.html(*2)NEC Open Innovation https://www.nec.com/en/global/innovation/index.htmlAbout ClimateAi, Inc.ClimateAi is a climate adaptation and resilience platform purpose-built for the agriculture, food, and consumer goods sectors. It combines AI-powered weather modeling with phenological and water-scarcity data to deliver highly localized, crop-specific agricultural impact insights across the short, medium, and long term. With deep expertise in climate–agriculture interactions and a client base that spans agricultural and consumer-goods multinationals as well as agricultural investors, ClimateAi turns complex climate data into actionable insights. For more information, visit ClimateAi at https://www.climate.aiAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.  Copyright 2025 JCN Newswire via SeaPRwire.com.

19 8 月, 2025

Value Research Center to host The Valuism Conference 2025 on August 28-29 (Hybrid Format)

KYOTO, August 19, 2025 - ACN Newswire via SeaPRwire.com - The Value Research Center at Doshisha University proudly announces The Valuism Conference 2025, taking place August 28–29, 2025, in a hybrid format, both in-person in Kyoto and online. The conference will run daily from 9:00 AM to 6:00 PM JSTA New Framework for Value CreationThis inaugural Valuism gathering aims to advance a novel integrative framework, Valuism, designed to address pressing challenges in sustainability, long-term resilience, and multi-stakeholder value creation. Attendees will explore how philosophical insight, cutting-edge technologies (e.g., AI, blockchain, big data), and cross-sector collaboration can foster transparency, ethical decision-making, and real-time measurement of value.Featuring keynote speeches, expert panels, and interactive sessions, The Valuism Conference 2025 will cover:- Philosophical foundations and real-world applications of Valuism Strategies for monetizing and scaling intangible assets - The role of emerging technologies in sustainable and ethical business practices- Cross-sector approaches that benefit companies, communities, shareholders, employees, and the environment.Registration and TicketingA range of ticket options accommodates different audiences:General Admission (in-person) - ¥15,000, Corporate Admission (for up to 3 participants) - ¥40,000, Online only Admission - ¥5,000, Student Admission - ¥3,000, Students from Kansai universities (Doshisha University, Osaka University, Kyoto University, Kobe University and Kansai University) can attend for free.The Valuism Conference 2025 offers a unique opportunity for leaders in academia, business, government, and civil society to shape a more holistic and responsible value paradigm for the 21st century.For full program details, speaker bios, and registration, visit: The Valuism Conference 2025 page on the Value Research Center site. https://www.valueresearchcenter.com/valuismconference2025 About the Value Research CenterFounded in November 2021, the Value Research Center (VRC) at Doshisha University is dedicated to developing frameworks, metrics, and reporting tools that capture value generated or lost across seven stakeholder domains: the organization, shareholders, customers, employees, partners, society, and the planet. https://www.valueresearchcenter.com Contact: Value Research Center, Doshisha University Email: psugai@mail.doshisha.ac.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

19 8 月, 2025

Fujitsu signs new licensing agreement with Palantir

Kawasaki, Japan, August 19, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the signing of a new licensing agreement with Palantir Technologies Japan for the Palantir Artificial Intelligence Platform (Palantir AIP), a software that supports the integration of generative AI into business operations. The agreement, signed on August 5, 2025, will allow Fujitsu to provide Palantir AIP to its customers in Japan, with global expansion expected during fiscal 2025. Fujitsu will also combine Palantir AIP with Fujitsu Uvance, its business model to solve societal issues, to facilitate business transformation for its customers in Japan and around the world. This agreement will further strengthen the strategic global partnership between Fujitsu and Palantir.Fujitsu and Palantir began their collaboration in 2020, focusing on data integration and digital transformation support in the Japanese market. In 2023, the two parties signed a global agreement, under which Palantir grants Fujitsu the right to market and distribute Palantir Foundry, a platform currently offered for integrated management of large-scale data dispersed across various systems.When combined with Palantir Foundry, Palantir AIP enables the rapid implementation of generative AI functionalities for data analysis and decision-making within enterprises. It can be used with a preferred large language model (LLM) within corporate networks and is adopted extensively in highly confidential sectors such as finance and defense. By leveraging Palantir AIP, customers can design and develop systems utilizing generative AI and AI agents in a fraction of the time of conventional methods, enabling faster optimization of supply chains, automation of business workflows, and to empower executive decision-making.Fujitsu currently offers solutions that combine its operational expertise with Palantir Foundry for data integration and analysis, optimizing operations in areas such as supply chain and engineering. The integration of Palantir AIP into Fujitsu Uvance will introduce unified support for generative and agentic AI tasks including scenario simulation, root cause analysis, and proposal generation and further optimize business processes. Furthermore, by linking with Fujitsu's AI services such as Takane and Fujitsu Kozuchi, Fujitsu will enhance Japanese language capabilities and business-specific functionalities, and facilitate the rapid implementation of agentic AI for customers with Japanese language requirements. This will contribute to the realization of data-driven autonomous decision-making workflows that transcend traditional visualization-centric analyses while retaining the indispensable oversight and expertise of human practitioners.In its internal trials using Palantir AIP, Fujitsu found that the platform can optimize human resource utilization, such as appropriate engineer placement and improved matching accuracy through skill analysis and produced results including reduced workload and faster decision-making. With the full-scale utilization of Palantir AIP within Fujitsu now possible, the company will integrate data from internal core systems and further advance management visualization and decision-making enhancement, including mechanisms for early detection and prediction of various risks related to its supply chain (i.e., natural disasters, financial, and compliance risks, etc.) and enabling rapid response.Through this partnership, Fujitsu aims to achieve sales of USD 100 million by the end of fiscal 2029 by providing high-value-added offerings and supporting advanced decision-making for customers across various industries, including manufacturing, retail, government, and finance. Palantir will provide the Palantir AIP platform and continuous functional enhancements, along with technical support for expanding use cases through collaboration with Fujitsu.Going forward, under Fujitsu Uvance, Fujitsu will leverage generative AI to provide foundational infrastructure for information sharing and data utilization that connects the workplaces and management in real-time, contributing to the realization of a more sustainable future.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries  Copyright 2025 JCN Newswire via SeaPRwire.com.

19 8 月, 2025

中国生物制药(1177.HK)公布2025中期业绩

重点成果- 期内,集团共有2个创新产品获中国国家药品监督管理局(「NMPA」)批准上市,分别为普坦宁(美洛昔康注射液(II))和安启新(注射用重组人凝血因子VIIa N01)。- 2025年上半年,集团创新产品收入达到人民币78亿元,同比增长27.2%。除创新产品外,集团还有5个仿制药获NMPA批准上市,整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日,集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中,2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段;11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期;另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维(盐酸安罗替尼胶囊)是一种新型小分子多靶点酪氨酸激酶抑制剂,目前已获批9个适应症,另有3个适应症处于上市申请阶段。此外,安罗替尼还有多项新适应症处于III期临床研究阶段,包括一线非鳞状非小细胞肺癌、一线胰腺癌等,预计将在未来两年逐步递交上市申请。- 2023-2024年,集团共有5款肿瘤领域的国家1类创新药获批上市,分别为:亿立舒(艾贝格司亭α注射液)、安得卫(贝莫苏拜单抗注射液)、安柏尼(富马酸安奈克替尼胶囊)、安洛晴(枸橼酸依奉阿克胶囊)和安方宁(格索雷塞片);以及4款肿瘤领域的生物类似药获批上市,分别为:安倍斯(贝伐珠单抗注射液)、得利妥(利妥昔单抗注射液)、赛妥(注射用曲妥珠单抗)和帕乐坦(帕妥珠单抗注射液)。该等产品在2025年上半年快速放量,成为集团收入增长的重要贡献品种。- 拉尼兰诺(泛PPAR激动剂)是一种口服小分子药物,用于治疗代谢功能障碍相关脂肪性肝炎(MASH),目前正在全球开展III期临床试验,已完成全部受试者入组。2023年7月,拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物,有望填补中国市场空白。- 天晴速畅(吸入用布地奈德混悬液)是中国首款获批上市的布地奈德雾化剂型仿制药,打破了国内市场长期被原研垄断的局面,为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围,集团及时采取了一系列主动管理措施,包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安(氟比洛芬凝胶贴膏)是中国首个获批上市的国产凝胶贴膏,连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发,深入拓展市场覆盖,并逐步扩大产能以满足市场的旺盛需求,推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级,二代产品可显著提高药物透皮吸收度,增强贴膏粘附性,从而提升患者的依从性。香港,2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2025年6月30日止6个月(「期内」)之未经审核财务业绩。回顾期内,集团收入同比增长10.7%至约175.7亿元(人民币,下同)。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元,同比增长约140.2%,基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利(非香港财务报告准则指标)约30.9亿元,同比增长约101.1%。集团流动资金保持充裕,期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元,理财管理产品总额约92.9亿元,资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙(2024上半年:3港仙)。销售:研发创新动能强劲,多领域销售成果持续放量集团一直以来重视研发,持续加大投入以提升研发质效,研发实力显著增强,驱动销售收入持续增长,成果丰硕。期内,抗肿瘤用药之收入同比增加24.9%,达约66.9亿元,占集团收入约38.1%。外科/镇痛用药之收入同比增加20.2%,达约31.1亿元,占集团收入约17.7%。肿瘤领域,集团全面布局非小细胞肺癌领域,覆盖多种分型的全线治疗,EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床,EGFR/cMet双抗ADC TQB6411 I期临床正在入组,两款产品进度均位于中国前列;深度布局乳腺癌三大亚型, CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法,HER2双抗ADC TQB2102较DS-8201潜在安全性优效,多个适应症正在同步拓展,其中三项乳腺癌III期快速推进;系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿,LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快,且目前临床数据展示出了极大潜力。于外科╱镇痛领域,集团持续聚焦高潜力地区开发,深入拓展市场覆盖,并逐步扩大产能以满足市场的旺盛需求。期内,集团推动泽普思销售额持续快速增长,而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时,2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势,有望成为该领域新的增长动力。研发:全力以赴推动创新产品开发,加大研发的资金投入于报告期内,集团共有2个创新产品获NMPA批准上市,分别为普坦宁(美洛昔康注射液(II))和安启新(注射用重组人凝血因数VIIa N01)。2025年上半年,集团创新产品收入达到人民币78亿元,同比增长27.2%。除创新产品外,集团还有5个仿制药获NMPA批准上市,整体仿制药收入在2025年上半年保持正增长。一直以来,集团十分重视研发,不断提升研发水平和速度,并视其为可持续发展的基础,加大研发的资金投入。截至二零二五年六月三十日止六个月,研究与开发成本约人民币318,756万元,占本集团收入约18.1%,连同已资本化的研发总开支出在内,约95.7%已计入损益表中。展望:深化创新与国际化布局,加速构建全球医药创新竞争力当前,中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下,我国生物医药创新能力显著提升,创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能,更在全球市场逐步崭露头角,日益获得广泛认可,已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业,集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域,专注创新,服务病患,目标成为全球领先的制药企业。集团深耕中国市场,同时将战略视野投向全球市场,以国际化加速创新发展。同时,集团大力推进全球战略合作布局,通过商务拓展(BD)、战略收购等多元合作路径,快速充实创新管线储备,强化核心技术平台。2025年7月,集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台,包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台(LM-Abs™),新一代抗体偶联药物平台(LM-ADC™)、以及免疫细胞衔接器平台(LM-TCE™)。此次收购将进一步增强集团的创新研发能力,加速集团的创新业务增长。此外,礼新医药卓越高效的研发团队将加入集团,进一步强化集团的创新研发人才储备,为持续产出高水平创新成果提供保障,助力创新生态的长远发展。未来,本集团将继续聚焦创新,提升四大治疗领域的研发效率与质量,加快国际化步伐,力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司(股票编号:1177)中国生物制药,连同其附属公司,是中国领先的创新研究和研发驱动型医药集团,业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药,在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市,2013年入选MSCI全球标准指数之中国指数成分股;2018年入选恒生指数成分股;2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」,连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料,请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

19 8 月, 2025

Team Mitsubishi Ralliart Triumphs at Asia Cross Country Rally 2025 with Chayapon Yotha’s Overall Victory and Team Award

TOKYO, August 18, 2025 - (JCN Newswire via SeaPRwire.com) – Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Team Mitsubishi Ralliart, which receives technical support from the company, has won first place in the Asia Cross Country Rally (AXCR) 2025, held in Thailand from August 8 to 16. The team competed with the Triton1 pickup truck (T1 specification, or modified cross-country vehicle), covering a total distance of 2,316.32 kilometers (km), including 1,002.95 km of Special Stages (SS)2.Team Mitsubishi RalliartIn the overall standings, Chayapon Yotha secured first place with a total time of 16 hours, 15 minutes and 12 seconds; Katsuhiko Taguchi finished in fifth place; and Kazuto Koide placed 22nd overall. The team also earned the Team Award – given to teams with three or more finishers based on the combined time of their top two vehicles – for the second time, and the first in two years.This year’s AXCR kicked off with a ceremonial start at Walking Street, a well-known tourist spot in Pattaya, Thailand. The rally officially began the following day with Leg 1, traveling roughly 360 km northeast from Pattaya to Prachin Buri in eastern Thailand. This leg featured the rally’s longest SS, spanning 199.13 km.Leg 2 took competitors about 500 km north from Prachin Buri to Khao Yai. The SS included a mix of rocky terrain and high-speed sections through plantations, highlighting the diverse landscapes AXCR is known for. Leg 3 remained in the Khao Yai area, where the already demanding course was made even tougher by afternoon squalls that turned the roads muddy, causing many vehicles to struggle.Legs 4 and 6, originally planned to run within 50 km of the Cambodian border, were canceled due to safety concerns. Leg 5 proceeded as scheduled, returning to Prachin Buri for an SS near the city. Although the route followed the same path as SS1, the course had deteriorated significantly due to deep ruts left by vehicles in Leg 1 and fallen trees caused by continuous rain. Even top teams were caught in the mud, making it one of the most grueling days of the rally.In Leg 7, the rally returned to Pattaya, retracing parts of the SS1 and SS5 routes. This stage featured narrow paths through plantations, pothole-ridden roads, and river crossings. The final day, Leg 8, concluded at Bali Hai Pier in Pattaya.Team Mitsubishi Ralliart Driver HighlightsChayapon Yotha, the team’s ace driver, started in 12th position but quickly climbed the ranks with strong times in Leg 1, ending the first day in second place. Thanks to precise navigation by co-driver Peerapong Sombutwong and consistent driving that pushed for speed while minimizing mechanical strain, he took the overall lead in Leg 3. Despite getting stuck in deep mud during Leg 5, he maintained an aggressive pace and recorded the second fastest SS time in Leg 7. He held onto the lead and won the rally by a narrow margin of seven minutes, claiming his second overall AXCR victory – his first in three years.Katsuhiko Taguchi began in a strong fifth position and remained among the frontrunners in the early stages. However, in Leg 3, rough terrain damaged the front suspension and dropped him to 10th overall. In Leg 5, where many vehicles struggled with deep mud, he overtook 18 competitors and posted the fastest SS time, recovering to sixth overall. Despite damage to the under guard and rear suspension on the demanding Leg 7 course, his determined driving earned him a fifth place overall – the highest among Japanese pairs – concluding his third AXCR challenge.Kazuto Koide, competing in his second year as a corporate driver, faced early setbacks. On the first day, poor visibility from dust led to a collision with a suddenly stopped vehicle, resulting in a day retirement, and in Leg 5, he experienced rear brake failure. Despite these issues, he supported teammates dealing with mechanical troubles in Legs 3 and 8, fulfilling his role as a support vehicle. He improved on last year’s result, finishing 22nd overall.Comments from Team Mitsubishi RalliartHiroshi Masuoka, Team Director“Winning was our top priority this year, and I am thrilled we achieved it while showcasing the strength and audacity of Mitsubishi Motors-ness. Securing the team award is a testament to the collective effort and determination of everyone at Team Mitsubishi Ralliart. By refining the Triton’s core strengths – its stability on high-speed stages and agility on winding roads – we gained a competitive edge over rivals with larger-displacement engines. Looking ahead to next year, we will continue to enhance the vehicle to further boost our competitiveness.”Chayapon Yotha, Driver of Car #112“I am truly happy to have claimed overall victory once again, thanks to the entire team playing their part perfectly and delivering a flawless vehicle. This year’s rally was extremely demanding, with rocky sections, mud, and slippery terrain. Yet, the Triton’s durability and exceptional handling allowed me to stay in control through high-speed corners and technical muddy stretches, delivering top-tier performance. I will be back next year to defend the championship.”Katsuhiko Taguchi, Driver of Car #105“Although I finished fifth again this year, I can clearly see how much our crew has improved. We consistently posted competitive times against larger-displacement vehicles across all stages, even recording the fastest SS time in Leg 5. The Triton continues to evolve year after year, and its suspension and handling capabilities were crucial in tackling rough terrain and contributing to Chayapon’s victory. After the rally, we identified areas where we can gain more time, so with thorough testing to build on our strengths, I am confident we can achieve even better results next year.”Kazuto Koide, Driver of Car #118“Although the rally was mentally demanding, especially with a day retirement, it was an invaluable experience. The Triton I drove was equipped with an automatic transmission using standard production components, yet it proved remarkably resilient even under the harsh conditions of AXCR. The handling and maneuverability I experienced will provide valuable feedback for future vehicle development, and I look forward to applying these insights to the next generation of Mitsubishi models.”AXCR 2025 Auto Category – Overall Standings1.Chayapon Yotha (Mitsubishi Triton)16 h 15 m 12 s2.Mana Pornsiricherd (Toyota Hilux Revo)16 h 23 m 03 s3.Bailey Cole (Ford Raptor)17 h 08 m 29 s4.Ditsapong Maneein (Isuzu D-Max)17 h 09 m 32 s5.Katsuhiko Taguchi (Mitsubishi Triton)17 h 37 m 56 s6.Natthaphon Angritthanon (Toyota Hilux Revo)17 h 46 m 52 s…22.Kazuto Koide (Mitsubishi Triton)29 h 34 m 31 sRally reports are available on Ralliart’s official Instagram account. https://www.instagram.com/ralliart.official/AXCR Special Website:https://www.mitsubishi-motors.com/en/brand/ralliart/axcr/axcr2025/1.Sold as L200 in some markets2.The actual distance was shortened due to course changes.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first veh icle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2025 JCN Newswire via SeaPRwire.com.

19 8 月, 2025

UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System

Tokyo, Japan, August 18, 2025 - (JCN Newswire via SeaPRwire.com) — NEC Corporation (NEC; TSE: 6701) today announced the signing of a Memorandum of Understanding (MOU) with the United Nations Population Fund (UNFPA) (*1), which promotes activities to protect the health and rights of women and girls, to collaborate on the development of a beneficiary information management system.Both parties will promote digitization in the management of beneficiary information supported by the UNFPA and implement privacy-conscious operations, thereby contributing to the provision of rapid, safe, and secure support. This system will be implemented in Nigeria and Madagascar by the end of 2025, supported by the Ministry of Foreign Affairs in Japan and aiming to build on this partnership in other parts of the world.NEC Chief of Staff for the CDO and Head of the Marketing & Alliance Promotion Department, Mayuko Tatewaki (left), UNFPA Director, Division for External Relations, Ian McFarlane (center left), UNFPA Director, Information Technology Solution Office, Soren Thomassen (center right), and UNFPA Chief, Representation office in Tokyo, Japan, Eiko Narita (right)The UNFPA is the United Nations sexual and reproductive health agency. The UNFPA’s mission is to deliver a world where every pregnancy is wanted, every childbirth is safe and every young person's potential is fulfilled. The agency began operating in 1969 and currently works with partners in more than 150 countries to provide access to a wide range of sexual and reproductive health services.In recent years, an increase in international conflicts, and natural disasters caused climate change have led to ongoing social and economic unrest around the world. Amidst this situation, it is imperative to promote sexual and reproductive health and rights (SRHR), including addressing gender-based violence (GBV) against women and girls.To address these challenges more rapidly and safely, the UNFPA and NEC will establish a beneficiary information management system based on an e-Voucher system, which is NEC's solution for the registration and management of beneficiary information, that digitizes and centrally manages information such as names, addresses, and details of the support provided for beneficiaries, which was previously managed on paper. This will enable the UNFPA to accurately identify the needs of beneficiaries, such as the kinds of support required for each region, and to develop support plans accordingly, thereby achieving swift and effective support delivery.Additionally, to appropriately handle beneficiary information containing sensitive content, the system will be designed to ensure the privacy of beneficiaries, and the UNFPA will receive NEC training on data literacy, ensuring safe and secure operations that prioritize privacy protection.Moreover, NEC will participate in the 9th Tokyo International Conference on African Development (TICAD 9) (*2) at Pacifico Yokohama in Yokohama, Japan, from August 20 (Wed.) to 22 (Fri.), 2025. At this event, NEC will introduce its initiatives at the TICAD Business Expo and Conference exhibition hall (*3) and at the UNFPA-planned event stage (*4)."This is a great partnership opportunity that leverages resources from both public and private sectors for a greater impact on the ground, especially for women and girls to enjoy their ‘rights and choices’."Ian McFarlane, Director, Division for External Relations, UNFPA"We are pleased to contribute to the UNFPA's acceleration of its activities around the world by leveraging NEC's digital technology. We are confident that this collaboration will bring about digital transformation in the fields of humanitarian aid and global health."Mayuko Tatewaki, Chief of Staff for the CDO and Head of the Marketing & Alliance Promotion Department, NEC(*1)United Nations Population Fund https://www.unfpa.org/(*2)The 9th Tokyo International Conference on African Development (TICAD 9) https://www.mofa.go.jp/region/africa/ticad/ticad9/index.html(*3)NEC to participate in "TICAD Business Expo and Conference" and thematic events for TICAD 9https://www.nec.com/en/press/202508/global_20250805_03.html(*4)Investing in Peace: Digital Transformation (DX) in Health for Adolescent Youth and Women https://tokyo.unfpa.org/ja/event/ticad9_thematic (scroll down the link for English)About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.  Copyright 2025 JCN Newswire via SeaPRwire.com.

19 8 月, 2025

斩获12金14银11铜 摘得大满贯!首程控股多家被投企业闪耀世界人形机器人运动会

香港,2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日,全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会,在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办,集聚全球 280 支战队、500 余台机器人同台竞技,展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中,首程控股(0697.HK)作为深度产业推动者,多家被投企业集体亮相,参与多个重点项目并获得优异成绩,共计斩获37枚奖牌,其中包括12金14银11铜(包括各战队使用被投企业本体机器人参赛获奖情况)。与此同时,首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店",成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节:宇树科技:在 2025 世界人形机器人运动会圆满落幕之际,宇树科技以出色的表现获得了四金,再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越,分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌,展现了其在速度、灵活性和稳定性方面的强大实力。此外,在本届赛事中,宇树科技的机器人最高速度达到了 4.78m/s,这一成绩距离其内部测试的 5+m/s 还有一定差距,未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩,分别获得了1金1银1铜,进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心:在2025世界人形机器人运动会上,北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力,累计斩获2金6银2铜,成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分,其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手,最终获得银牌;在 100 米项目中夺得金牌,在 400 米项目中拿下银牌与铜牌各一枚,并在 4×100 米接力赛中获得银牌,全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中,创新中心自主研发的天轶 2.0 机器人,凭借慧思开物"具身大脑+具身小脑"的智能协同体系,在"物料整理"项目中包揽金银牌,在"物料搬运"项目中斩获银牌与铜牌,并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力,充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位,北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越,也为具身智能的落地提供了极具参考价值的技术路径。松延动力:在本次运动会自由体操项目中,由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感,夺得冠军,展现出融合 AI 与动态模仿控制的高水平舞台表现力;博远智行 1 队采用松延动力机器人参赛,也在同一项目中荣获季军。在跳远项目中,松延动力的机器人再次发挥出色,赢得了冠军,展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中,松延动力联合北京舞蹈学院组建代表队参赛,凭借对细节动作的精准复现和对舞台艺术的深度理解,最终斩获亚军,成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜,不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力,也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用:在首届世界人形机器人运动会中,银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时,来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛,均成功闯入复赛,其中矿大与北建大更是闯入决赛,最终分获亚军与第四名。至此,冠亚军由银河通用及采用银河通用机器人的队伍共同包揽,充分展现了银河通用技术的行业引领性与产品的通用性。星海图:在本次运动会中,星海图深度参与赛事生态构建,作为场景赛独家整机提供商,提前三周入驻实训场,为来自全国的 20 余支顶尖团队(包括北京林业大学、清华大学、北京航空航天大学等)提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备,并搭建开放软硬件平台,支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括,酒店服务(床铺整理、迎宾行李搬运)、仓储中心(混合物料分拣)、医院场景(药品识别与补货)及工业场景(异物分拣与物料搬运)。走进冰丝带,就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中,来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛,并成功获得季军,充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化:作为足球项目的核心技术支持方,加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人,承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称,展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛,但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现,是足球项目"幕后冠军"。二、科技体验走进生活,打造机器人产业"样板间"大会期间,首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品,涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块,成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示:"我们希望通过这次展示,让大家感受到机器人离生活越来越近。场馆内比的是专业能力,我们的体验店则通过贴近真实场景的互动设计,拉近机器人与大众的距离。"体验店内各展区的亮点纷呈:生态展示区以松延动力为代表,展示具备表情识别、人脸互动能力的拟人机器人,体现大模型与形态融合的前沿趋势;儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备,是全店人气最高区域;外骨骼与康复区设置跑步机、自行车等模拟设备,观众可实地体验机器人助力运动;智能穿戴区引入光粒品牌游泳眼镜,具备实时导航和运动数据采集能力;人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品,深受观众欢迎;同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等,体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业,全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营,但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业,后续还将布局至全国多个城市与重点场景(机场、高校、商圈等),形成连锁化、场景化的销售与体验网络。叶芊表示:"我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口,也希望通过这类门店,持续验证市场需求、推动产品优化,帮助更多机器人企业走向商业化落地。"四、每一块奖牌,都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出:"这场运动会,不仅比拼技术的高度,更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来,首程控股将持续依托"股权投资+资产运营"双轮驱动战略,携手被投企业与行业伙伴,推动机器人从看得见、摸得着的技术突破,走向用得上、可推广的现实应用,在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

18 8 月, 2025

Anime Tokyo Station Surpasses 200,000 Visitors

TOKYO, Aug 18, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an exhibition center for Japanese anime operated by the Tokyo Metropolitan Government and the Association of Japanese Animations, is a facility that promotes the appeal of Japanese anime to the world under the motto “Making ANIME more interesting, Bringing ANIME far into the future.” The facility has welcomed numerous visitors from Japan and overseas, and on August 3, 2025, the number of visitors surpassed 200,000.The 200,000th visitors were a group of three from Fukuoka and Kanagawa Prefectures, and they shared their surprise and delight: “Today we happened to pass by Anime Tokyo Station and decided to come in because we love anime. We didn’t know this facility existed. We’re surprised to be here at such a commemorative moment—celebrating the 200,000th visitor.” When asked about which exhibits left an impression on them, they commented, “We were amazed to see the anime production materials archive and the anime production process exhibits on the first basement floor. It really hit us that anime is something that is actually created by people. It’s incredible.”Anime Tokyo Station preserves approximately 50,000 valuable materials related to past anime production processes. The facility serves as a launch point into the world of anime,  where a variety of people such as travelers visiting Tokyo from all over the world can gather and enjoy discovering both past masterpieces and the latest popular series. Going forward, we will share the appeal of anime and Tokyo with a wide range of anime fans both in Japan and overseas.Venue Overview- Name: Anime Tokyo Station (also known as "Anime Tokyo")- Location: Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from the East Exit of Ikebukuro Station- Hours: 11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions last admission: 6:30 p.m.)- Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.- Admission fee: Free- Website: https://animetokyo.jp/en/- SNS:X | https://x.com/animetokyo_info (@animetokyo_info)Instagram | https://www.instagram.com/animetokyostation/ (@animetokyostation)YouTube | https://www.youtube.com/@アニメ東京ステーションInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20250818.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com.

18 8 月, 2025

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China

TOKYO, August 18, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO® (brand name in China: “DAYVIGO®“ generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in China on May 27, 2025. This marks the first orexin receptor antagonist to be launched in China.DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). Unlike conventional treatments such as benzodiazepines that act directly on sleepiness, DAYVIGO acts on the orexin neurotransmitter system, which regulates wakefulness. DAYVIGO is believed to facilitate sleep on set and sleep maintenance, and wake by regulating sleep-wake rhythm by suppressing hyperactive wakefulness. DAYVIGO binds to orexin receptors OX1R and OX2R and acts as a competitive antagonist with stronger inhibition effect on OX2R, which suppresses both REM and non-REM sleep drive, such that DAYVIGO may provide faster sleep onset and better sleep maintenance to patients.Insomnia is characterized by difficulty falling asleep, staying asleep, or both despite an adequate opportunity to sleep, that has occured at least three times a week for at least one month, and which can lead to fatigue, difficulty concentrating and irritability.1,2 The prevalence of insomnia among adults in China is reported to be 15.0%3, with approximately 172.5 million people thought to suffer from insomnia.4 Currently, the mainstream prescription drugs for insomnia in China are treatments that act directly on sleepiness, and there is increasing demand for new treatment options.Eisai will deliver novel action mechanism, DAYVIGO, as a new treatment option to Chinese insomnia patients with the hope of contributing to restoration of daytime function and recovery for patients with insomnia by potentially delivering an active daytime life through fast sleep onset and good quality sleep.“DAYVIGO®” Product OutlineChinese Trade name:(DAYVIGO)Chinese generic name:(Lemborexant Tablets)Indication for use: Insomnia in adults that characterized by difficulties with sleep onset and/or sleep maintenance Dosage and administration: The recommended dosage of DAYVIGO is 5 mg taken once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum dose of 10 mg.About DAYVIGO (Generic Name: Lemborexant)DAYVIGO, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant’s potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in more than 25 countries including Japan, the United States, Canada, Australia and countries in Asia.1. Ferrie JE, et al. Sleep epidemiology – a rapidly growing field. Int J Epidemiol. 2011;40(6):1431–1437.2. Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–S10.3. Cao X-L, et al. The prevalence of insomnia in the general population in China: A meta-analysis. PLoS ONE 2017,12(2):e0170772.4. Internal estimateMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.

18 8 月, 2025

艾曲莫德入选《2025 ACG临床指南:成人溃疡性结肠炎》,获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗

香港,2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布,旗下创新药艾曲莫德(VELSIPITY(R),etrasimod)被纳入《2025 ACG 临床指南:成人溃疡性结肠炎》(下称"新版指南"),并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎(UC)患者的诱导缓解及维持缓解治疗(中等质量证据)。新版指南同时建议,对于已通过鞘氨醇-1-磷酸(S1P)受体调节剂实现诱导缓解的患者,继续使用艾曲莫德以维持缓解(强烈推荐,中等质量证据)。这一重要进展不仅体现了国际权威医学指南对艾曲莫德临床价值的高度认可,也进一步彰显了其在满足UC患者未被满足的治疗需求方面的潜力,为全球UC患者提供新的治疗选择。此次新版指南由美国胃肠病学会(American College of Gastroenterology,ACG)制定,基于近五年最新循证医学证据,系统总结了UC治疗及并发症预防的新方法与新进展,为临床医生提供规范、科学的管理参考,以更好地应对不同程度的UC患者治疗需求。新版指南指出,艾曲莫德作为新一代高选择性S1P受体调节剂,通过将活化的淋巴细胞滞留于淋巴结中,减少其在肠道中的浸润,从而降低局部炎症反应,并伴随外周循环淋巴细胞计数下降。艾曲莫德ELEVATE UC III 期注册研究(ELEVATE UC 52和ELEVATE UC 12)这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点,分别在第12周和第52周显著改善临床缓解率,并实现持久的内镜下深度黏膜愈合。值得注意的是,研究中100%的临床缓解均为无激素缓解,安全性良好,与既往研究结果一致。指南也特意强调了与其他现有治疗不同的是,艾曲莫德 ELEVATE UC III 期注册研究中纳入了溃疡性直肠炎,且证实了在此类人群中显著提升了临床缓解率(治疗12周时,43.2% vs 13.6%, p<0.001)。此前,艾曲莫德还被纳入2024年美国胃肠病学协会(AGA)临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。艾曲莫德亚太临床试验牵头研究者、世界胃肠病学会司库、亚太消化病学会副主席、中华医学会第十届消化病学分会副主任委员、中国人民解放军第四军医大学附属西京医院吴开春教授表示:"新版指南进一步明确,'实现内镜黏膜愈合以达成持续无激素缓解和避免住院手术'是中重度溃疡性结肠炎治疗的核心目标,这不仅关系到疾病的长期安全管理,也与改善患者生活质量息息相关。此次指南中,艾曲莫德被强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗,标志着其临床价值获得了国际权威学术机构的高度认可,也为临床实践提供了全新的治疗选择。"云顶新耀首席执行官罗永庆表示:"艾曲莫德此次获新版指南强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗,充分体现了其卓越的临床疗效和良好安全性,进一步确立了其作为一线治疗新选择的重要地位。新版指南明确将实现内镜黏膜愈合作为治疗中重度活动性溃疡性结肠炎的核心目标,印证了黏膜愈合为国内外指南一致认定的重要终点,可显著降低疾病复发、住院、结直肠切除及结直肠癌风险。值得一提的是,指南特别强调了艾曲莫德在溃疡性直肠炎患者中同样可显著提升临床缓解率。在亚洲,溃疡性结肠炎患者人数持续上升,以中国为例,2024年中国的溃疡性结肠炎患者数量约为80万人,预计到2030年将达100万人,现有临床治疗选择有限,迫切需要兼顾疗效、安全性与便利性的创新方案。我们将加速艾曲莫德的商业化进程,助力更多患者长期维持安全有效的疾病缓解,并提升生活质量。"作为云顶新耀在自身免疫疾病领域布局的核心创新产品,艾曲莫德(维适平(R))的新药上市申请已于2024年12月获中国国家药品监督管理局正式受理,预计今年年底或明年年初获批。艾曲莫德已在新加坡、中国澳门和中国香港获批,其新药上市许可申请也已在韩国和中国台湾地区获正式受理。艾曲莫德已被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录(2024年),在大湾区先行使用,成为云顶新耀第三款商业化新药。云顶新耀已于2025年3月启动艾曲莫德在嘉善工厂的本地化生产建设项目,支持其在大中华区及其他亚洲市场的供应及商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

16 8 月, 2025

业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元

业绩亮点:- 收入达83.6百万美元,同比增长5.9%。- 销量达919,000件,其中779,000件为自有产品,同比增长8.6%。- 公司拥有人应占利润同比上升5.1%至19.8百万美元。- 核心经营利润达15.1百万美元,同比增长11.4%。- 为庆祝集团成立25周年,董事会宣派特别股息每股15港仙。- 财务状况稳健,截至2025年6月30日,现金及银行结余达237.1百万美元,支持潜在收购及新生产设施建设。- 优质产品获全球广泛认可,带动亚太地区市场收入按年增长14.0%,欧洲、中东及非洲市场增长17.0%,及美国市场增长20.0%。- 于上半年收购一家台湾经销商,并计划下半年于比利时及荷兰设立直销团队,进一步加强在亚太地区及欧洲、中东及非洲市场的影响力。- 集团善用全球商业化专长及庞大销售网络,与医疗器械同业建立战略合作,藉此丰富产品组合,并透过交叉销售创造额外收入。香港,2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司("业聚医疗"或"集团";股份代号:6929)今天宣布截至2025年6月30日止六个月("报告期")的中期业绩。尽管宏观经济环境未见明朗,集团的收入及纯利仍双双录得增长。美国市场增长强劲,加上亚太地区及欧洲、中东与非洲地区新兴市场的持续贡献,推动集团收入达到83.6百万美元,较去年同期上升5.9%。核心经营利润(自本公司拥有人应占利润撇除以股份为基础的薪酬开支、与税务亏损相关的递延税项资产的税务抵免净额及融资收入╱成本)为15.1百万美元,同比增长11.4%。公司拥有人应占利润同比上升5.1%至19.8百万美元。每股基本盈利为2.40美仙(2024年上半年:2.28美仙)。截至2025年6月30日,集团财务状况保持稳健,现金及银行结余达237.1百万美元。鉴于集团的财务状况稳健,以及为庆祝成立25周年,董事会议决宣派特别现金股息每股普通股15港仙,彰显集团致力为股东创造价值。连同截至2024年12月31日止年度之末期股息每股10港仙(已于2025年6月16日派付),股东于2025年合共获派股息每股25港仙。业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示:"过去25年,我们持续投资于创新及全球商业化能力,除了为业聚医疗建立了声誉,也助我们在不同的经济周期中破浪前行。尽管2025年上半年面临宏观经济及地缘政治的双重挑战,我们的全球布局仍展现韧性。美国市场增长印证了市场对我们的优质产品需求殷切,而我们亦透过庞大的销售网络,成功把握了亚太地区及欧洲、非洲及中东地区的增长机遇。我们将继续透过直销市场覆盖、卓越的销售支援、对创新的投入,以及全面的PCI和PTA产品组合提升品牌价值,从而强化竞争优势,为医生及患者提供更安全有效治疗方案的同时,也为股东创造长远回报。"全球销售网络及合作伙伴关系推动收入增长业聚医疗已建立覆盖逾70个国家及地区的销售网络,在13个地区设立直销团队并建立全球经销商网络,成为把握各地机遇、回应当地需求的重要一环。期内,受惠于印尼市场增长,以及Scoreflex TRIO 在新加坡及马来西亚获更广泛采用,亚太地区收入同比上升14.0%至27.3百万美元。欧洲、中东及非洲市场方面,德国、法国及西班牙等直销市场及包括英国、斯洛伐克及捷克共和国在内的分销市场的自有球囊类产品销售表现强劲,带动该区收入上升17.0%至22.4百万美元。尽管受关税因素影响,美国市场收入仍同比上升20.0%至8.0百万美元,主要受冠脉的普通及刻痕球囊,包括高价产品Scoreflex NC球囊,以及外周球囊销量显著上升所推动。而日本及中国境内市场的收入分别为16.1百万美元及9.7百万美元。凭借其广受认可的全球商业化能力,集团与立志走向国际巿场的同业合作,藉此丰富产品组合并开拓额外收入来源。继去年与深圳开立生物医疗科技股份有限公司成功展开合作,在香港及澳门分销血管内超声产品后,集团与该伙伴再度签订独家分销协议,在新加坡及马来西亚分销相关产品。至目前为止,合作范围已进一步扩展至集团旗下位于欧洲的4个直销市场,包括法国、德国、西班牙及瑞士,及其他6个分销市场。性能主导的多元化创新产品组合,提升市场差异化水平截至2025年6月30日,业聚医疗在全球主要司法管辖区拥有逾250项授权专利及已公布专利申请,及逾55款获批产品。期内,集团产品注册及临床试验继续取得进展,包括:- Sapphire 3的美国临床试验进展顺利,预期于2025年第四季度完成病人入组,以支持该产品的FDA纳入CTO适应症,从而与市场上其他传统半顺应性球囊形成差异化;- JADE PLUS及Teleport Glide获得CE标志、Teleport Glide及Scoreflex QUAD获得PMDA批准、COREPASS模组化微导管获得FDA批准、导引导管获得国家药监局批准;- 就Scoreflex TRIO、Sapphire ULTRA、Sapphire NC ULTRA、Sapphire NC 24、JADE PLUS、Teleport XT及Teleport Glide向国家药监局提交注册申请,并就Vascuaid抽吸导管及大管腔延长导管向PMDA提交注册申请。集团拥有庞大的产品管线。在冠状动脉领域,Sapphire PTX紫杉醇药物涂层球囊大约于2025年底在日本展开临床研究;外周方面,JADE Score球囊则预期于2026年向PMDA提交注册申请。合资企业业聚培福在中国境内展开的TricValve临床试验亦取得重大进展,参与医院数量上升,加快了病人入组进度。此外,业聚培福亦正透过"港澳注册药品及医疗器械进入大湾区计划",积极推动大湾区各大医院采用TricValve。TricValve于2025年7月完成首次在中国境内进行的商业化植入手术,达到重要的里程碑。多区域生产基地缓解地缘政治风险截至2025年6月30日,业聚医疗于中国深圳、荷兰荷佛拉肯,以及德国莱茵河畔魏尔设有生产基地,总年产能约为210万件球囊及支架。自2023年底收购eucatech AG以来,集团已投入资源恢复其生产能力,期内产量逐步提升,以供应销售及临床注册所需产品。2025年8月,集团完成位于中国杭州、旗下最大研发及生产基地的主体结构建设,装修工程预期于下半年展开。该基地计划于2027年投产,届时将新增年产能240万件。钱先生总结说:"有见于新兴市场的强劲势头、自研产品陆续成功推出巿场,以及已建立的战略合作,我们对2025年下半年前景保持乐观。除了亚太地区及欧洲、中东及非洲将继续担当主要的增长引擎,我们亦计划将部分市场由分销模式转为直销模式,以强化当地营收能力及市场渗透。欧洲市场将透过于比利时及荷兰设立直销团队加强市场影响力;日本市场则藉新产品上市重拾增长动力;而在中国境内市场,我们则把握政策支持,扩大产品覆盖并加速商业化进程。随着关税争端缓和,美国市场的产品交付亦有望加快。凭借业聚医疗多元化的产品组合、稳健的财务状况及规模经济效益,我们具备优势构建具韧性及竞争力的业务体系,为持份者创造可持续的价值。"关于业聚医疗集团控股有限公司业聚医疗是一家全球医疗器械制造公司,专门生产用于经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)的介入器械。本集团总部位于中国香港,产品销往全球超过70个国家和地区。集团亦积极将业务扩展至结构性心脏病领域。凭借拥有逾20年产品开发经验的内部研发团队,本集团已开发出世界领先的专有技术。如需了解更多详情,请访问集团官网:https://orbusneich.com/ Copyright 2025 亚太商讯 via SeaPRwire.com.

16 8 月, 2025

广发证券荣膺国家数据管理能力成熟度(DCMM)最高等级认证

广州,2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 近日,中国电子信息行业联合会公布最新一批获颁数据管理能力成熟度(简称"DCMM")等级证书企业名单,广发证券获评最高等级五级(优化级)认证,成为行业首家获评最高等级的证券公司,标志着公司在数据管理和应用方面达到国内领先水平,为行业数据管理能力建设树立标杆。《数据管理能力成熟度评估模型》(GB/T 36073-2018)是我国数据管理领域正式发布的首个国家标准。该认证从数据战略、数据治理、数据架构、数据应用等多个维度,全面评估企业的数据管理能力。其中,五级(优化级)作为最高等级,标志着企业的数据管理已形成行业最佳实践,具备强大的示范引领作用。一直以来,广发证券高度重视数据管理能力的建设与提升,将数据视为企业核心资产。公司构建了"战略引领、全员参与、跨部门协同、全生命周期管理"的数据管理体系。通过制定清晰的数据战略规划,完善数据治理组织架构与制度流程,强化数据安全与合规管理,持续提升数据质量与应用效能,公司实现了数据管理从"规范"到"优化"的跨越式发展,为业务创新、客户服务升级及风险管理提供了强有力的数据支撑。广发证券副总经理、首席信息官辛治运表示:"公司将以此次获得DCMM五级认证为新的起点,持续深化数据管理能力建设,进一步完善数据治理长效机制,推动数据技术与业务场景的深度融合,并以此为契机,不断提升服务实体经济的质效,为证券行业的数据管理创新与发展贡献更多力量。" Copyright 2025 亚太商讯 via SeaPRwire.com.

16 8 月, 2025

越秀房产基金整体经营稳定 实现收入逾人民币9.66亿元

香港,2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 越秀房地产投资信托基金(「越秀房产基金」,连同越秀房托资产管理有限公司,统称「基金」;股份代号:405)公布其截至2025年6月30日止六个月之中期业绩。越秀房产基金管理团队:主席及非执行董事江国雄先生(中)、执行董事及行政总裁区海晶女士(左)、财务总监关志辉先生(右)2025年中期业绩摘要:- 整体经营稳定,收入总额为人民币9.66亿元(2024年同期:人民币10.34亿元)。- 于2025年6月30日,物业整体出租率为82.2%(2024年同期:84.0%)。- 平均融资成本为3.33%,较年初下降83个基点,剔除汇兑亏损的融资成本同比减少13.5%。- 中期分派每个基金单位约人民币0.0333元,约等于0.0366港元。按年计算的分派收益率为8.42%。广州国金中心:- 广州国金中心综合体录得经营收入为人民币4.86亿元,占基金收入总额50.3%。- 广州国金中心写字楼引进一家财富世界500强背景企业;出租率为82.6%;续约率为70%。- 国金天地期内出租率高达96.4%。- 广州四季酒店平均入住率同比上升1.1个百分点,客房收入创历史同期新高;国金中心雅诗阁服务式公寓平均入住率同比增长1.8个百分点,营业收入亦创历史同期新高。广州越秀金融大厦:- 越秀金融大厦录得经营收入约人民币1.65亿元,占基金收入17.1%,出租率达82.1%。- 租户结构不断优化,新引进优质租户包括一家财富世界500强背景企业,以及一家市值超百亿的期货企业。积极管理融资风险,有效平抑融资成本- 针对2025年上半年到期的人民币5.3亿元短期贷款、21亿港元5年期银团贷款及今年内到期的其他贷款,管理人于2025年上半年完成人民币5.3亿元短期贷款续借,并通过取得人民币17亿元境外贷款和发行人民币10亿元点心债,用于到期贷款的再融资及提前置换,确保流动性风险得到有效管控。- 管理人期内合计引入人民币32.3亿元贷款,并置换境外浮息港元贷款,利用人民币融资相对低位,主动调节融资结构,降低利率市场冲击。2025年上半年末融资利率敞口约为14%,较年初26%收窄12个百分点;平均融资成本为3.33%,较年初4.16%下降83个基点;上半年平均付息率3.92%,同比下降64个基点。剔除汇兑亏损的融资成本约为人民币4.02亿元,同比减少13.5%。- 2025年6月末人民币融资约147.95 亿元,占总体融资72%(2024年同期:人民币融资约84.04 亿元,占总体融资41%)。越秀房产基金主席及非执行董事江国雄先生表示:「2025年上半年,在全球贸易环境波动及经济增长放缓的背景下,中国国内生产总值GDP同比增长5.3%,但企业扩张保守缓慢;零售消费疲弱、酒店公寓房价承压。为应对行业不利因素,我们策略性抢占市场份额,提前推进续租工作,投入资本性改造,提升产品竞争力,有效稳住经营基本面,为中期经营收入提供坚实支撑。同时,融资成本回落也为分派创造有利条件。」国金中心国金中心透过提升产品和优化营运,客户访问量和转化率均录得正向提升,新签13,133平方米。推出4,235平方米带装修单元去化周期仅约十九天,去化率接近九成。引进优质租户包括一家财富世界500强背景企业、一家全球龙头航运企业和一家知名互联网背景文体娱乐企业,合计超过2,200平方米。续租9,099平方米,续租率70%,留存优质租户包括两家财富世界500强背景企业和一家外国领事馆。国金中心入选观点「表现力指数·2025商办资产运营表现」TOP30榜单。国金天地积极打造电子化消费场景,推进悦秀会本地生活平台试点落地,已覆盖12家商户,同时利用大众点评、云闪付等平台多渠道引流,新签和续租合计5,734平方米,续租率97%。出租率为96.4%。期内,中免免税店宣布落户国金天地,预计第三季度开业,成为广州首家且目前唯一的市内免税店。广州四季酒店客房收入和国金中心雅诗阁服务式公寓营业收入分别创历史同期新高。广州四季酒店期内平均入住率为80.1%,同比上升1.1个百分点;平均房价为人民币2,201元,与去年同期相若;每间可供出租客房收入(RevPAR)为人民币1,762元,同比增长0.7%;RevPAR竞争指数为111.7,在奢华酒店竞争群组中始终保持较领先的市场地位。国金中心雅诗阁服务式公寓期内平均入住率为92.3%,同比上升1.8个百分点,平均入住率高于竞争群公寓9.7个百分点;平均房价为人民币1,128元,与去年同期相若;RevPAR为人民币1,041元,同比增长1.5%;RevPAR竞争指数达120.0。越秀金融大厦越秀金融大厦期内新签7,448平方米,包括七家租户扩租合计1,500平方米。推出7,089平方米带装修单元,去化周期约38天,去化率超过六成半。新引进优质租户包括一家财富世界500强背景企业,以及一家市值超百亿的期货企业。受部分租户回迁自有物业办公的影响,续租10,303平方米,续租率42%。留存大面积优质租户包括国际四大之一「德勤」和一家国内龙头综合性资产管理公司。白马大厦白马大厦引入珠三角供应链资源,期内带动新签3,273平方米,实现一楼满租。上半年累计接待165个采批团,累计接待采购商近5,000人次,其中包括来自法国、越南等23个外商团,促成采购金额达人民币1.4亿元。白马大厦依托大湾区国际女装展、广交会等展会促进租户成交,亦成功推出「白马悦境通」跨境电商平台和「白马商学院营销赋能营」系列课程,激活租户数字化运营新动能。财富广场财富广场期内新签2,354平方米,引进优质租户包括一家财富世界500强综合金融集团旗下医疗养老板块的数家企业。续租2,924平方米,续租率76%,留存优质租户包括一家财富世界500强背景企业,亦灵活匹配降本需求调整单元挽留租户。城建大厦城建大厦期内新签7,585平方米,引进一家美容科技企业提升楼内大健康业态氛围。结合租户降本意愿制定挽留方案,优化产品标准匹配租户需求。续租2,090平方米,续租率68%,包括一家全球知名合同研究组织(CRO)的广州办公室。维多利广场维多利广场期内主力租户「优衣库」继续发挥旗舰作用,首发C系列产品,并于3月28日至4月6日落地全国首场「优衣库美好生活市集」、巨型宝可梦及美好生活音乐活动,活动期间达季度客流峰值,带动四月销售额同比增长7%,推动中期期间销售额同比增长0.3%。项目联动餐饮租户,抓住客流高峰提升销售,带动中期期间项目整体销售额同比增长0.6%。上海越秀大厦上海越秀大厦期内续租3,798平方米,续租率39%;新签3,933平方米,迅速填补退租单元。通过更换停车场节能灯管提升场内亮度,项目实现节能效益和服务水平双提升,提高租户满意度。于中期期末,上海越秀大厦出租率为87.2%,同比增加2.6个百分点。武汉物业武汉越秀财富中心期内新签12,395平方米,引进优质租户包括一家全球领先汽车集团成员企业和一家多元化专业服务企业。续租10,884平方米,续租率81%,留存大面积优质租户包括一家财富世界500强背景央企。招商团队透过单元局部微改造、软装提升、打造智能样板间等多种方式优化客户看楼体验,提升客户转化率。星汇维港购物中心期内新签和续租合计3,894平方米,续租率82%。成功引进多家热门餐饮品牌,包括A馆一楼引进网红品牌「达美乐」,带动更多家庭客群。项目开拓夜间消费,利用四楼「悦花园」亮点优势,持续打造「江畔星夜」、「深夜食堂」激发销售新增长点。杭州维多利杭州维多利期内新签1,974平方米,引进一家全层租户。续租6,083平方米,续租率64%,留存优质租户包括一家财富世界500强背景建筑工程企业和一家山西省属国企的浙江分公司。未来展望市场普遍憧憬美联储下半年进一步降息,但路径和幅度仍具不确定性。另一方面,今年是中国「十四五」规划收官之年,各项政策稳字当头,包括适度宽松货币政策和「以旧换新」消费补贴政策,旨在通过扩大内需激发市场活力,因此管理人预期人民币利率将维持较低水平。伴随国内新质生产力加快培育发展和供给侧改革深化推进,管理人预期产业动能继续推陈出新,营商气氛将向好改善。备受瞩目的第十五届全国运动会将于下半年在广州开幕,有望带动商场消费和酒店公寓需求。下半年,管理人将因应经济发展走势动态实施积极、稳健、灵活的租赁策略,敏锐把握潜在机会,持续提升资产组合市场竞争力。管理人将视市场发展预期对融资结构持续检视并进行合理调整,通过各类人民币融资途径,引入低成本人民币融资,以寻求更优融资成本,平滑利率风险。管理人将按计划开展相关资本性改造工程,合理规划和分段改造广州四季酒店客房,围绕产品提升、设备更新和安全保障维度,实现物业保值增值,为项目稳健经营保驾护航。关于越秀房地产投资信托基金越秀房地产投资信托基金(「越秀房产基金」)于2005年12月21日在香港联交所上市,为全球首只投资于中国内地物业的上市房地产投资信托基金。越秀房产基金目前持有的物业组合包括位于广州的广州国际金融中心、白马大厦、财富广场、城建大厦、维多利广场、越秀金融大厦、位于上海的越秀大厦、位于武汉的武汉物业(包括武汉越秀财富中心和星汇维港购物中心)、位于杭州的维多利商务中心以及位于香港的越秀大厦共10项高素质物业,物业产权面积共约118.4万平方米,分别位于中国广州市、上海市、武汉市、杭州市及香港市的核心商业区域。物业类型包括甲级写字楼、商业综合体、零售商业、酒店、服务式公寓、服装专业市场等。传媒查询:纵横财经公关顾问有限公司李惠儿电话: +852 2864 4834电邮:sprg_yx@sprg.com.hk梁家仪电话: +852 2114 4172张铭伊电话: +852 2864 4903网址:http://www.sprg.com.hk  Copyright 2025 亚太商讯 via SeaPRwire.com.

15 8 月, 2025

云顶新耀维长宁(艾曲莫德)在中国台湾新药上市申请获受理 亚洲市场准入再迎里程碑

香港,2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布,中国台湾地区药政主管部门(TFDA)已正式受理维长宁(艾曲莫德,中国台湾地区商品名:"維長寧")用于治疗中重度活动性溃疡性结肠炎(UC)患者的新药上市许可申请(NDA)。这一进展标志着艾曲莫德继在中国澳门、新加坡和中国香港获批以及韩国NDA获正式受理之后,在亚洲市场的准入取得又一重大里程碑。中国国家药品监督管理局也于2024年12月正式受理艾曲莫德(维适平(R))的新药上市申请,预计将在今年年底或明年年初获批。艾曲莫德是一款针对溃疡性结肠炎,每日一次的口服一线治疗药物,能够强效实现肠道黏膜愈合,且使用便捷,并具有良好的安全性特征。黏膜愈合是国内外溃疡性结肠炎临床指南一致认定的溃疡性结肠炎治疗目标。溃疡性结肠炎患者尽早实现黏膜愈合,可大幅降低疾病复发率、住院率、结直肠切除手术率和结直肠癌发生风险。艾曲莫德已被纳入2024年美国胃肠病学协会(AGA)临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。2025年,艾曲莫德获得2025年美国胃肠病学会(ACG)成人UC临床指南的一线治疗推荐,进一步印证了其全球专业共识下的临床价值。云顶新耀首席执行官罗永庆先生表示:"此次在中国台湾地区NDA申请的正式受理,是维长宁亚洲商业化进程中的又一重要进展。随着亚洲地区溃疡性结肠炎患者人数持续增长,临床上存在巨大未满足需求。仅在中国,2024年溃疡性结肠炎患者数量约为80万人,预计到2030年将达100万人。患者面临长期治疗与生活质量的双重挑战。此次受理充分体现了对维长宁临床价值的高度认可。我们将继续加快这一创新疗法在中国大陆及亚洲其他市场的上市进程,提升可及性,帮助患者实现长期疾病控制并改善生活质量。"本次申请基于ELEVATE UC III期注册研究(ELEVATE UC 52和ELEVATE UC 12)和ENLIGHT研究(ES101002)的结果。ELEVATE UC III期注册研究显示,在既往常规治疗、生物制剂或JAK抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者中,每日一次2mg艾曲莫德在第12周和第52周均显示卓越且持久的临床缓解和内镜下深度黏膜愈合,且安全性良好,与既往研究一致。同时,ENLIGHT研究作为迄今最大规模的亚洲中重度UC III期注册临床研究,在中国大陆、中国台湾及韩国开展,共纳入340名患者。研究结果显示,艾曲莫德在诱导期和维持期均取得了显著且具有统计学意义的疗效优势,为其在亚洲人群中的应用提供了有力证据支持。作为云顶新耀在自身免疫性疾病领域的重磅产品,艾曲莫德已于2024年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录,在大湾区先行使用,惠及UC患者,并成为公司第三款商业化新药。今年3月,云顶新耀已启动艾曲莫德在嘉善工厂的本地化生产建设项目,以支持其在大中华区及亚洲其他市场的供应与商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

15 8 月, 2025

TANAKA Holds Press Conference to Commemorate Its 140th Anniversary

TOKYO, Aug 15, 2025 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) celebrated the 140th anniversary of its founding in July 2025. To commemorate the occasion, it held a "140th Anniversary Press Conference" on July 31 at KABUTO ONE in Nihonbashi Kabutocho.TANAKA PRECIOUS METAL GROUP Co., Ltd. CEO Koichiro TanakaSpeaking at the press conference were Koichiro Tanaka, Group CEO of TANAKA PRECIOUS METAL GROUP Co., Ltd., Masakazu Tanaka, CEO of TANAKA PRECIOUS METAL RETAILING Co., Ltd., and Tomoyuki Tada, COO of TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. The three reflected on TANAKA’s history as a leading company in the precious metals industry, from its head office in Nihonbashi Kayabacho, where the Group was founded, and highlighted its contributions to society through precious metals.Turning to the Group's future outlook, the speakers clarified plans to strategically focus on two pillars of business: retail business and industrial business. They presented TANAKA’s ambidextrous management approach, which aims to achieve ultra-long-term growth leading up to the Group’s 200th anniversary in 2085 and reflects TANAKA’s commitment to creating present-day value while actively embracing future challenges.Contents of speakers' presentationsLooking back on the Group's 140 years of history, Group CEO Koichiro Tanaka provided an overview of its current business and presented how it has taken on new challenges and innovated. He followed with an explanation of the Group's overall future strategies and its vision for growth, and also announced a business partnership with JEPLAN, Inc., with the goals of reducing CO2 emissions from precious metal recovery processes and recycling organics. Group CEO Tanaka commented, "TANAKA, which has worked to create a circular economy in the field of precious metals, and JEPLAN, which has worked toward the same goal in the plastics field, will work together to help achieve decarbonization and create a circular society."CEO Masakazu Tanaka touched on how the retail business has changed and its current business situation, explaining what direction TANAKA would take with the products in its asset and jewelry businesses and its strategies for responding to the increasingly diverse needs of customers. He also talked about how the Group would promote more accurate knowledge about gold and raise awareness regarding gold trading through ongoing communications. During his presentation, he announced that from November 21, 2025, the names of the Group's directly-operated shops would change from GINZA TANAKA to TANAKA PRECIOUS METALS to unify its precious metals retail business.Lastly, COO Tomoyuki Tada addressed the current state and future direction of technological innovation and market expansion in industrial precious metal products, discussing in particular the Group's approach of accelerating the realization of a circular society by linking precious metal recycling and product manufacturing. He also discussed how the Group was working to build and expand its global recycling system by further deepening its collaboration with Group company Metalor Technologies SA, and emphasized the Group’s commitment to building a sustainable and healthy society through its pioneering efforts in key areas such as the hydrogen economy, semiconductors, and medical fields. His presentation also introduced technology development projects aimed at creating new demand for platinum group metals and showed the Group's desire to take advantage of future growth potential.TANAKA PRECIOUS METAL RETAILING Co., Ltd.CEO Masakazu TanakaTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.COO Tomoyuki TadaThe event site also had a timeline of the Group's 140-year history, graphs of changes in gold prices released by TANAKA, exhibitions of products and services offered by the Group in the retail business segment, industrial precious metal products, and industrial precious metal technologies.Panels showing TANAKA's 140-year long history and changes in the prices of gold and platinum Retail Business: Featured Products Industrial Business: Featured Products To realize the TANAKA Renaissance Plan, an ultra-long-term company management plan for leading up to the Group’s 200th anniversary in 2085, TANAKA will continue to promote technical and business development. Through the creation of value in emerging fields, TANAKA aims to contribute to a brighter and more sustainable future.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group's consolidated net sales for the fiscal year ending December 2024, was 846.9 billion yen.TANAKA PRECIOUS METAL GROUP Co., Ltd.TANAKA Corporate Websitehttps://www.tanaka.co.jp/english/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.co.jp/support/req/other_contact_e/index.htmlPress release: https://www.acnnewswire.com/docs/files/20250815.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com.

15 8 月, 2025

RAK ICC以2025年立法升级加强基金会制度

阿联酋拉斯海马市, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 阿勒哈伊马国际公司注册中心(RAK ICC)宣布对其2019年《基金会条例》进行重大修订,新规已于2025年7月31日生效。此次修订是该制度自推出以来最为重要的更新之一,进一步巩固了阿联酋作为财富架构与长期资产保护竞争性司法辖区的地位。RAK ICC基金会因其灵活性、保密性及法律稳健性而广受认可,成为阿联酋国内外高净值人士、企业家及家族办公室的首选架构工具。这类结构通常用于继承规划、家族治理,以及将多元化资产整合于单一法律实体之下。2025年的修订引入了更强的法律保障及改进的治理措施,包括:1. 防火墙条款 —— 对与RAK ICC法规相冲突的外国判决提供更强有力的保护。2. 三年诉讼时效 —— 将对基金会设立或资产转移提出异议的时限限制为三年。3. 诉因条款 —— 债权人欺诈索赔仅限于涉案的特定资产,且仅在该行为导致创办人资不抵债时才适用。4. 胁迫与高管保护 —— 宣告在外国法律胁迫下采取的行为无效,从而保障基金会内部治理的自主权。5. 强化仲裁机制 —— 允许通过具备法院级权力的私下仲裁方式解决争议。6. 私人受托基金会条款 —— 明确基金会作为受托人持有财产时的资产隔离及受信义务的完整性。在RAK ICC基金会持有的资产现将享有更强的防火墙保护,确保与阿联酋法律相冲突的外国判决无法对其执行。新规设立了三年的时效期,用于限制对基金会成立或资产转入的质疑,为创办人及受益人提供更大的确定性。改革还收紧了债权人保护规则,在欺诈性转让索赔中须证明创办人资不抵债,并将责任限定在争议资产的价值范围内,以防涉及无关财产。此外,修订后的法规着重维护治理完整性和运营韧性。基金会高管在收到与RAK ICC法律不一致的外国命令时,必须予以忽略,从而保障基金会决策的自主权。新框架明确规定,基金会作为受托人持有的信托财产在法律上独立且与基金会自有财产分离,确保资产隔离的清晰性。争议解决机制也得到了强化,扩大的仲裁条款赋予仲裁庭类似法院的权力,使争议能够高效、保密地解决,并符合国际最佳实践。这些变化是RAK ICC维护前瞻性法律与监管环境整体战略的一部分,旨在满足全球标准的同时兼顾客户群体的特定需求。这也体现了该司法辖区在支持兼顾控制、隐私与长期安全的高端财富规划策略方面的承诺。通过强化其基金会制度,RAK ICC正巩固其在阿联酋的地位,成为寻求安全、灵活且符合国际合规标准的财富保全与跨代规划解决方案的可信赖合作伙伴。关于RAK ICC阿勒哈伊马国际公司注册中心(Ras Al Khaimah International Corporate Centre,简称RAK ICC)是一家总部位于阿联酋阿勒哈伊马的公司注册机构。该机构提供国际商业公司及基金会架构,通常用于私人及商业结构设计、资产整合以及继承规划。截至目前,RAK ICC已注册成立数千家国际公司,并为数十亿迪拉姆的结构化资产提供支持。其服务对象包括高净值人士、企业家及寻求灵活、安全的长期商业与财富管理方案的企业。媒体咨询请联系我们:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/来源: RAK ICC Copyright 2025 亚太商讯 via SeaPRwire.com.

14 8 月, 2025

卫龙美味公布2025年中期业绩

香港,2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 中国辣味休闲食品行业龙头企业,卫龙美味全球控股有限公司("卫龙美味"或"集团")及附属公司("集团")( 香港联交所股票代码:09985)公布截至2025年6月30日止六个月("期内")之中期业绩。人民币截至6月30日止六个月2025年2024年变动收入34.83亿29.39亿+18.5%毛利16.42亿14.62亿+12.3%毛利率47.2%49.8%-2.6个百分点期内净利润7.36亿6.21亿+18.5%净利润率21.1%21.1%保持稳定中期股息0.18元/普通股0.16元/普通股+12.5%2025年上半年,在全球消费增长普遍承压下,中国消费市场依然是全球最大消费市场之一。 得益于中国休闲食品市场近年来呈现出稳健的增长态势,报告期内,卫龙美味紧跟行业发展趋势,坚持多品类产品策略,聚焦创新,深度开展消费者洞察,精准捕捉市场需求,持续强化研发实力,并持续以年轻人喜爱的方式深化品牌渗透,通过各种线上线下的品牌活动搭建多维消费场景链接深化品牌渗透,持续推进全渠道覆盖能力和销售网络,进而为客户及消费者提供更好的服务和体验。报告期内,卫龙美味经营策略成效彰显,业绩持续稳健攀升,收入与净利润均录得双位数增长。2025年上半年实现总收入34.83亿元(人民币,下同),同比增长18.5%,主要由于集团期内持续加强全渠道和品牌建设,并优化渠道结构。尽管报告期内部分原材料成本上涨导致集团毛利率由去年同期的49.8%下降2.6个百分点至47.2%,但在收入增长及集团积极提升供应链效率的共同因素驱动下,毛利仍同比增长12.3%至16.42亿元。同时受惠于集团经营利润的提升,集团期内净利润同比增长18.5%至7.36亿元;净利润率得以维持去年同期水平,为21.1%。基于期内整体绩效表现,集团董事会决议派发2025年中期股息每股人民币0.18元,派息比率约为60%,预计派付股息日期为2025年10月20日或前后。产品方面,集团坚持多品类产品策略,从新产品、新口味、新工艺、新包装等维度发力,如拓展风味创新边界,深度回应消费者对创新口味的需求。2025上半年,集团先后先后推出了麻酱口味"魔芋爽"以及麻辣牛肉口味"亲嘴烧"等多个新品,进一步拓展并丰富产品组合,提升产品品质,满足市场多元化及个性化的消费需求,驱动产品力与市场需求匹配。品牌建设方面,集团持续以年轻人喜爱的方式深化品牌渗透,透过各种线上线下的品牌活动搭建多维消费场景链接,譬如联合林里柠檬茶发起"爆辣挑战",凭借爆款销量与话题效应触达更多消费者;携手国潮品牌哭喊中心推出"大儿童专属"系列,借节日营销勾起青春味觉记忆。此外,集团于报告期内官宣王安宇担任魔芋爽代言人,借力明星影响力拓宽传播路径。集团的一系列举措有效触达年轻客群,夯实了品牌年轻化与趣味化的发展根基。渠道方面,集团持续推进线下全渠道、线上全平台覆盖策略。随着各种新兴渠道业态的兴起,集团紧跟渠道变化,持续拓展终端网点,强化销售团队终端执行力,并联合经销商持续提升终端的服务能力和产品铺市率,从而有力推动线下终端业绩稳步增长。在线上领域,集团同样积极布局,构建全平台生态体系,确保与线下渠道形成有效联动,助力全渠道发展战略落地。此外,集团始终致力于生产设施的自动化升级与技术创新突破,同步加快各业务系统的数字化转型进程。在此基础上,集团不断强化组织发展与核心人才梯队建设,以此全面提升公司整体运营效能,为业务的持续稳健发展注入强劲动力。卫龙美味董事长刘卫平先生表示:"集团将始终坚守"多品类"产品策略,坚持产品创新,持续加码品牌建设力度,不断强化卫龙"年轻、有趣、有创意"的品牌形象与独特调性。与此同时,集团积极拥抱变化,持续加强全渠道的覆盖能力,为消费者提供更便捷的消费体验。展望未来,集团将以更积极、更主动的心态拥抱市场的变化,以更好的产品、更优质的服务和体验不断提升我们的竞争力,持续为消费者、客户、员工、投资人及社会创造更大的价值。"关于卫龙美味全球控股有限公司卫龙美味全球控股有限公司("卫龙美味")是中国领先的集研发、生产及销售为一体的辣味休闲食品企业,拥有强劲的增长势头和颇具影响力的品牌。 卫龙美味以传统美食为基础开创了中国调味面制品(俗称辣条)行业,于2001年开创出第一根辣条,并引领了辣条行业标准建设。 凭借出众的品类拓展能力,本集团已成功扩展至蔬菜制品、豆制品及其它产品等品类,推出了包括魔芋爽、风吃海带、小魔女等大单品。 卫龙美味是倍受中国年轻消费者喜爱的休闲食品品牌,拥有有效触达年轻消费者的全渠道销售及经销网络。 如欲获得更多信息,请浏览: https://www.weilongshipin.com/。 Copyright 2025 亚太商讯 via SeaPRwire.com.

14 8 月, 2025

TANAKA PRECIOUS METAL GROUP宣布将与JEPLAN进行业务合作以实现脱碳与循环型社会

东京, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd.(总公司:东京都中央区、执行总裁:田中 浩一朗)决定与株式会社JEPLAN(总公司:神奈川县川崎市、代表取缔役 社长兼执行总裁:高尾 正树、以下简称“JEPLAN”) 开展业务合作,以减少TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.在贵金属回收工艺中的CO₂排放,并推进有机物的资源化再利用。本次合作由长期致力于在贵金属领域推动循环经济(Circular Economy)的TANAKA、以及在塑料领域持续精进技术的的JEPLAN携手推动,旨在实现脱碳化和循环型社会的目标。TANAKA迄今为止为实现循环型社会所方面的努力TANAKA自1885年创业以来,作为贵金属行业的领军企业长年致力于稀缺资源贵金属的回收。其中受客户委托回收的工序废弃物中,对于以有机物(塑料)为主要成分、且附着或吸附有贵金属的工序废弃物,一直以来通过烧成工艺去除有机物,并从剩余的灰烬中回收贵金属。尽管这种烧成处理方式能够有效去除环境管制物质,但在去除过程中有机物燃烧所产生的CO₂排放,成为实现脱碳社会的课题。通过与JEPLAN业务合作、革新贵金属回收工艺JEPLAN已建立了针对聚对苯二甲酸乙二醇酯(PET,一种塑料)的创新化学回收技术。为了解决上述CO₂排放量的课题,TANAKA通过与JEPLAN的业务合作,除了传统的采用烧成的贵金属回收工艺以外,还在考虑未来利用化学回收处理的工艺。预期的化学回收处理的对象为注射器、擦拭布等塑料。预计通过该技术,贵金属回收工艺中的CO₂排放量可控制在以往的10%左右。此外,该新工艺不仅可以回收贵金属,也可以实现塑料再生,TANAKA与JEPLAN将充分发挥各自在专业领域的优势,共同为实现脱碳和循环型社会贡献力量。  株式会社JEPLAN总公司所在地:神奈川县川崎市川崎区扇町12-2成立:2007年1月代表人:代表取缔役 社长兼执行总裁 高尾 正树主要业务内容:PET化学回收技术相关业务(对象:PET塑料瓶、聚酯)等官方 HP:http://www.jeplan.co.jpJEPLAN集团以“循环一切”为使命,致力于实现循环经济。通过使用创新的PET化学回收技术,将废弃PET(PET塑料瓶、聚酯纤维等)分解至分子水平并去除杂质,使其重新生成与石油基材料同等品质的再生材料。通过使用这项创新技术致力于回收再利用,实现有限资源的循环,并为减少CO₂排放量做出贡献。关于TANAKATANAKA自1885 年(明治18年)创业以来,营业范围以贵金属为中心,并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售,以及提供作为宝石饰品及资产的贵金属商品。并且,作为贵金属相关的专家集团,日本国内外的各集团公司进行制造、销售以及技术一体化,携手合作提供产品及服务。2024年度(截至2024年12月)集团总营业额为8,469亿日元,拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20250814_CN.pdf  Copyright 2025 亚太商讯 via SeaPRwire.com.

14 8 月, 2025

Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US

TOKYO, August 14, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Corporation (“MC”) is pleased to announce that it has reached an agreement to acquire a 30% interest in the Copper World copper mine project (the “Project") owned by Hudbay Minerals Inc. ("Hudbay") for a total consideration of USD 600 million (approximately JPY 87 billion), consisting of USD 420 million (approximately JPY 61 billion) as consideration for equity interest and USD 180 million (approximately JPY 26 billion) as matching contribution which will be allocated toward development costs. MC and Hudbay will jointly conduct a definitive feasibility study for the Project.The U.S. is the world's second-largest consumer of copper, and steady demand growth is expected to continue, driven by population growth, increased power demand from generative AI and data center expansion, and the shift toward electrification. Arizona, where the project is located, accounts for approximately 70% of domestic copper mine production and is a leading mining region with strong access to key infrastructure. The project has already secured the permits required for development and commencement of operations, and is expected to start around 2029, with an anticipated output of approximately 100,000 tonnes of copper per year at peak. There is also potential for future mine expansion by securing permits to access adjacent mining concessions.Hudbay has cultivated extensive experience in mine development and operations since its establishment in 1927. The company currently operates three copper and gold mines and holds two other development projects in addition to the Project. MC has long been engaged in a wide range of businesses in North America, primarily in the U.S., and has invested in various mineral resources through partnerships with mining companies globally. Regarding copper, MC aims to expand its annual equity production to over 400,000 tonnes from FY2030 onwards, leveraging its expertise in global copper mining investments and trading activities. This investment is part of MC’s efforts to achieve that target. MC will advance a definitive feasibility study together with Hudbay, aiming for a final investment decision around 2026, drawing on MC’s knowledge in copper mining investment and extensive business experience across diverse sectors in North America developed over many years.As outlined in its Corporate Strategy 2027, “Leveraging Our Integrated Strength for the Future,” announced in April 2025, MC aims to expand its equity-based resource production and strengthen its competitive edge through its value-creation framework: “Enhance, Reshape, and Create.” Copper is projected to see sustained long-term demand growth. At the same time, challenges such as declining ore grades are making new mine development more difficult, raising concerns about supply stability. MC remains committed to securing and maintaining a stable supply of copper resources, which is essential for achieving a decarbonized society.Copper World Project SiteProject OverviewLocationTucson, Arizona, USAMining MethodOpen PitOre Reserves*2 MtResource Estimate**5 MtProduction StartAround 2029Maximum Annual ProductionApproximately 100,000 tonnesLife of Mine20 years (potential for further expansion)*Economically mineable part of resources**Total quantity of minerals confirmed through geological surveysHudbay OverviewCompany NameHudbay Minerals Inc.HeadquartersToronto, Ontario, CanadaEstablished1927CEOPeter KukielskiListingsToronto Stock Exchange, New York Stock ExchangeBusiness ActivitiesDevelopment and operation of copper and gold mines in Canada, the United States, and Peru Mitsubishi CorporationMitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight business segments that span virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development and Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution.Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2025 JCN Newswire via SeaPRwire.com.

14 8 月, 2025

NMPA已受理亿胜生物关于EB12-20145P(HLX04-O)用于治疗湿性年龄相关性黄斑变性的生物制品许可申请

香港,2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司("亿胜生物"或"集团",股票代码:1061.HK)欣然宣布,集团针对重组抗VEGF眼内注射液EB12-20145P(HLX04-O)的上市注册申请("BLA")最近已被中国国家药品监督管理局("NMPA")药品审评中心("CDE")受理。该产品由集团与上海复宏汉霖生物技术股份有限公司("复宏汉霖",股票代码:2696.HK)合作开发,用于治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration, "wet-AMD")。此注射液EB12-20145P(HLX04-O)在中国患者中开展的III期临床研究("AURA-1")已于今年4月成功达到主要研究终点。AURA-1为一项多中心、随机、双盲、阳性对照的非劣效III期临床研究,旨在比较EB12-20145P(HLX04-O)与雷珠单抗玻璃体内注射(IVT)治疗新诊断的wet-AMD患者的有效性和安全性。除其BLA已获NMPA受理申请的AURA-1外,EB12-20145P(HLX04-O)的一项国际多中心III期临床研究(AURA-2)也在欧洲多个国家、澳大利亚、美国和中国顺利开展,AURA-2最后一名患者的最后一次访视已在2025年1月完成。未来,亿胜生物将不懈追求卓越,拥抱创新,持续推动对同类首创(First-in-class)与同类最优(Best-in-class)产品的创新研发,以满足未来更多的临床及商业化需求。关于湿性年龄相关性黄斑变性年龄相关性黄斑变性(AMD)是造成老年人视力损害和不可逆失明的主要原因之一[1],根据世界卫生组织报告,全球约有3000万AMD患者,每年约有50万人因为AMD而致盲[2]。AMD致盲患者中,以脉络膜新生血管(CNV)为特征的湿性年龄相关性黄斑变性(wet-AMD)比例高达90%。随着老年人口比例的不断上升,wet-AMD已经成为一个日益严重的社会医学问题,存在着巨大的未满足的临床需求[3]。随着眼底治疗方法的突破与发展,抗VEGF药物已成为wet-AMD的一线疗法[4],贝伐珠单抗玻璃体腔注射治疗wet-AMD的有效性和安全性也已在多项临床研究中得到验证[5-11]。关于亿胜生物(股票代码﹕1061.hk)亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业,拥有包括贝复舒(R)、贝复济(R)、贝复新(R)在内的六种基因工程药物在中国上市销售。此外,公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺(R)卵磷脂络合碘胶囊等的多元化产品组合,主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的44个区域办事处的支持下,在逾14,000家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台,亿胜生物在多个临床阶段拥有强大的项目管线,涵盖广泛的领域和适应症。参考文献[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展[J]. 国际眼科杂志, 2020(1). [2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. [3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116. [4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292. [5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459. [6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. [7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411. [8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9. [9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52. [11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 亚太商讯 via SeaPRwire.com.

14 8 月, 2025